Drug Trial Radar · NCT06678542
Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects
Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Sep 27, 2024
Primary completion
Feb 16, 2025
Study completion Feb 16, 2025
Sponsor
- Lead sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the relative bioavailability and pharmacokinetic profile of a single oral dose of the test formulation, GP681 Powder for Oral Suspension (20 mg/sachet), compared to the reference formulation, GP681 tablet (20 mg/tablet), in healthy Chinese male subjects. The secondary objectives are to assess the safety of a single oral dose of the GP681 Powder for Oral Suspension (20 mg/sachet) and GP681 tablet (20 mg/tablet) in healthy Chinese male subjects, as well as the palatability (taste acceptability) of the GP681 Powder for Oral Suspension.
Conditions
- Healthy Participants
Interventions
GP681 tabletDrug
GP681 tablet, 20 mg, single oral dose in each Group.
GP681 Powder for Oral SuspensionDrug
GP681 Powder for Oral Suspension, 20 mg, single oral dose in each Group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to 360 hours post-dose
- Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration[AUC(0-T)]Time frame: Up to 360 hours post-dose
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time[AUC(INF)]Time frame: Up to 360 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Women and Children's hospital of Ningbo University
Ningbo, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.